Neuphoria Therapeutics Inc.

NEUP | NASDAQ

Price Alert Chart Builder DCF Calculator

$3.05

-$0.01 (-0.33%)

At close: Oct 30, 2026, 4:00 PM ET

$3.05

$0.00 (0.00%)

After-hours: Oct 30, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.33%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

39.8

-0.4 pts

Fundamentals Average

Market Sentiment Neutral

Moat None

Sector Rank #536/1028 (Top 52%)

Full Analysis

Key Statistics

Market Data

Market Cap $16.5M

1D Range

3.05 3.11

52W Range

3.05 5.48

Valuation (TTM)

PE -0.42

PB 0.67

EV/EBITDA 0.26

Valuation (NTM)

Forward PE N/A

Forward PEG 0.01

Price Target $7.00

Cash Flow

FCF Yield -74849.6%

SBC Adj. FCF Yield -76979.5%

SBC Impact -2.9%

Margins

Gross Margin 43.5%

Operating Margin -1187.7%

FCF Margin -1052118.7%

Growth (CAGR)

Revenue 3Y | 5Y 4086.7% | 4.8%

Dil EPS 3Y | 5Y -194.4% | -113.3%

FCF 3Y | 5Y -150.4% | -99.6%

Returns

ROA -64.5%

ROE -77.0%

ROIC -49.4%

Financial Health

Net Cash

$19.83M

Current Ratio 27.85

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its l...

Sector Healthcare

Industry Biotechnology

Employees 1

IPO Date Dec 16, 2021

Website www.neuphoriatx.com

Fiscal Year July - June

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

$7.00

Upside

+129.51%

Buy (0)

Hold (1)

Sell (0)

Analyst Details ➞